Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 1
1(20.0%)
5Total
N/A(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07222605Not ApplicableEnrolling By Invitation

Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device

Role: collaborator

NCT07049341Not ApplicableEnrolling By Invitation

Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases

Role: lead

NCT03927040Not ApplicableCompleted

Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Role: lead

NCT04271163Phase 1Unknown

Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease

Role: lead

NCT02958930Not ApplicableCompleted

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Role: lead

All 5 trials loaded